MINDCURE Provides Update on Studies and Clinical Trials
MINDCURE Provides Update on Studies and Clinical Trials
Pre-Clinical UpdateVANCOUVER, BC, Nov. 4, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to provide an operational progress update on the strategic initiatives of its operating segments - MINDCURE Research and MINDCURE Technology.
公元前温哥華，2021年11月4日/美通社/-Mind Cure Health Inc.(CSE：MCUR)(場外交易市場代碼：MCURF)(法蘭克福機場市場代碼：6MH)(“MINDCURE”或“公司”)是迷幻藥先進專利技術和研究的領先企業，該公司高興地提供其運營部門--MINDCURE研究和MINDCURE技術--戰略舉措的最新運營進展。
MINDCURE Research:
MINDCURE研究：
Synthetic Ibogaine Production Update
In March 2021, MINDCURE announced the initiation of chemical synthesis routes for the production of fully synthetic ibogaine. In July 2021, the Company applied for patents on two routes to full chemical synthesis and initiated the production of Good Laboratory Practice ("GLP") ibogaine leading to the production of Good Manufacturing Practice ("GMP") ibogaine in order to scale and manufacture a global supply of fully synthetic ibogaine. MINDCURE is currently on schedule and expects to have GLP supply available for research partners beginning in Q2 of 2022.
合成伊波金生產最新進展
2021年3月，MINDCURE宣佈啟動生產全合成伊博甘的化學合成路線。在……裏面2021年7月此外，公司還申請了兩條全化學合成路線的專利，並開始生產良好實驗室規範(“GLP”)伊波建，從而導致生產“良好製造規範”(“GMP”)伊博金，以擴大和生產全球全合成伊波甘的供應。MINDCURE目前正在按計劃進行，預計從2022年第二季度開始為研究合作伙伴提供GLP供應。
Pre-Clinical Update
MINDCURE confirms that it is preparing to ship ibogaine drug material to its pre-clinical research partner. The material will initially be used for broad cardiac and neurologic screens, with the potential to conduct in-depth behavioral studies. This program has been identified as MSYNTH-001, and the Company expects results from the first studies during the first quarter of 2022.
臨牀前最新進展
MINDCURE證實，它正準備向其臨牀前研究夥伴運送伊波甘藥物材料。這些材料最初將用於廣泛的心臟和神經學篩查，有可能進行深入的行為研究。該項目已被確定為MSYNTH-001，該公司預計2022年第一季度的初步研究結果。
In addition to advancing the scale of its synthetic ibogaine program, MINDCURE continues to explore options for drug pipeline expansion. Two candidate selection programs are currently underway, known internally as MC-106 and MC-808. The Company will provide further information on these programs in the second quarter of 2022.
除了推進其合成ibogaine計劃的規模外，MINDCURE還在繼續探索藥物流水線擴展的選擇。兩個候選人選拔計劃目前正在進行中，內部稱為MC-106和MC-808。該公司將在2022年第二季度提供有關這些計劃的進一步信息。
Clinical Trial Update
MINDCURE has completed its draft research protocol for the use of MDMA and psychotherapy to treat female sexual hypoactive desire disorder, known as The Desire Project. The Company expects a pre-IND meeting with the FDA to be scheduled in the first quarter of 2022 and for its Phase 2 trial to begin by the third quarter of 2022. Further, site initiation and initial screening are planned for March 2022, with recruitment and enrollment to follow.
臨牀試驗最新進展
MINDCURE已經完成了使用MDMA和心理療法治療女性性慾減退障礙(稱為慾望項目)的研究方案草案。該公司預計將在2022年第一季度與FDA舉行IND前會議，並在2022年第三季度開始其第二階段試驗。此外，網站啟動和初步篩選計劃在2022年3月進行，隨後將進行招募和註冊。
"We are proud to report that MINDCURE's core research programs are progressing rapidly, showcasing our disciplined commitment to advancing MINDCURE's drug research and commercial production programs. Concurrently, we maintain a focus on identifying opportunities to expand our drug development pipeline," said Kelsey Ramsden, President & Chief Executive Officer of MINDCURE.
MINDCURE總裁兼首席執行官凱爾西·拉姆斯登説：“我們很自豪地報告，MINDCURE的核心研究項目進展迅速，顯示出我們對推進MINDCURE藥物研究和商業生產計劃的嚴謹承諾。同時，我們繼續把重點放在尋找擴大我們的藥物開發渠道的機會上。”
MINDCURE Technology:
MINDCURE技術：
Digital Platform iSTRYM Update
The Company released the minimum viable product ("MVP") of its digital therapeutics (DTx) technology, iSTRYM, into partner clinics across North America in August. MINDCURE is pleased to announce that it has exceeded its previously announced target and timeline of 10 clinics by the end of 2021. The Company has already partnered with 20 ketamine clinics in nine states in the US and three provinces in Canada and plans to expand to the broader mental health market in 2022.
數字平臺iSTRYM更新
8月份，該公司向北美各地的合作診所發佈了其數字療法(DTX)技術的最低可行產品(“MVP”)iSTRYM。MINDCURE很高興地宣佈，它已經超過了之前宣佈的到2021年底10家診所的目標和時間表。該公司已經與美國9個州和#年的3個省的20家氯胺酮診所建立了合作伙伴關係加拿大並計劃在2022年擴展到更廣泛的精神健康市場。
In addition, MINDCURE will begin full commercial deployment to all partner clinics in early 2022, with expansion plans to the UK and Europe by the fourth quarter of 2022.
此外，MINDCURE將於2022年初開始對所有合作伙伴診所進行全面商業部署，並計劃在2022年第四季度之前將業務擴展到英國和歐洲。
In addition to its recently announced letter of intent with Awakn Life Sciences Corp. to distribute their Ketamine for Alcohol Use Disorder ("AUD") protocol in North America via iSTRYM, MINDCURE will expand its selection of existing ketamine protocols with an additional MINDCURE developed protocol in the first quarter of 2022. The Company is continuing on its path toward becoming a leader in the distribution of best-in-class therapy protocols for both partners and providers.
除了最近宣佈與Awakn生命科學公司簽署意向書，通過iSTRYM在北美分銷他們的氯胺酮治療酒精使用障礙(“AUD”)協議外，MINDCURE還將在2022年第一季度推出另一種MINDCURE開發的協議，以擴大其現有的氯胺酮協議的選擇範圍。該公司正繼續朝着成為面向合作伙伴和提供者的一流治療方案分銷領域的領先者的方向前進。
Observational Study Update
MINDCURE is pleased to announce that its Integration Protocol Research Study is complete. As previously announced in March 2021, unconditional ethics approval from Veritas IRB was received for the study. The data has been amassed and findings incorporated into the MVP of iSTRYM. As a next step, the Company's research partners will submit findings for publication. Understanding integration protocols and practices is an important part of providing best-in-class care specific to psychedelic medicines in practice.
觀察性研究最新進展
MINDCURE高興地宣佈，其整合協議研究已經完成。正如之前在2021年3月宣佈的那樣，這項研究獲得了Veritas IRB的無條件倫理批准。這些數據已經收集起來，並將結果納入了iSTRYM的MVP。下一步，該公司的研究夥伴將提交研究結果以供發表。瞭解整合方案和實踐是在實踐中提供針對迷幻藥物的最佳護理的重要組成部分。
Corporate Update
企業動態
MINDCURE has further engaged Sandstone Media LLC ("Sandstone") to provide a broad range of product and brand awareness, marketing and media services, including message development, content creation, social media, advertising, marketing and retargeting, which may include related investor relations services. Sandstone will be paid up to USD$375,000 for the execution and management of the campaign.
MINDCURE進一步委託Sandstone Media LLC(“Sandstone”)提供廣泛的產品和品牌知名度、營銷和媒體服務，包括信息開發、內容創作、社交媒體、廣告、營銷和重新定位，其中可能包括相關的投資者關係服務。沙巖將支付高達375,000美元的執行和管理的活動。
Lastly, the Company has granted a total of 30,000 stock options to certain employees pursuant to the terms of the Company's long term incentive plan ("Plan"). The stock options are exercisable at a price of $0.33 per share and subject to the terms of the Plan.
最後，根據公司長期激勵計劃(“計劃”)的條款，公司已向部分員工授予共計30,000份股票期權。股票期權可按每股0.33美元的價格行使，並受該計劃條款的約束。
About MINDCURE
Mind Cure Health ("MINDCURE") is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.
關於MINDCURE
MinDCURE是一家生命科學公司，專注於創新和商業化促進康復和改善心理健康的新方法。該公司正在開發數字治療技術，並研究迷幻化合物，以支持在全球範圍內獲得安全的、基於證據的迷幻輔助治療。要了解更多信息，請訪問Mindcure.com，並在LinkedIn、Facebook、Twitter和Instagram上關注我們。
On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995
我謹代表董事會凱爾西·拉姆斯登，總裁兼首席執行官電話：1-888-593-8995
Forward-Looking Information
Certain information presented in this news release may constitute "forward-looking information" within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases.
前瞻性信息
本新聞稿中提供的某些信息可能構成有關MINDCURE及其業務的適用證券法所指的“前瞻性信息”。前瞻性信息一般可以通過使用諸如“預期”、“相信”、“可能”、“估計”、“預期”、“感覺”、“打算”、“可能”、“計劃”、“預測”、“項目”、“服從”、“將”、“將”等術語和短語來識別。
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE's business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE's products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders.
前瞻性信息基於MINDCURE管理層做出的一系列重要預期和假設，包括但不限於：“新冠肺炎”疫情對加拿大經濟和MINDCURE業務的影響，以及這種影響的程度和持續時間；對MINDCURE業務產生負面影響的法律法規不會發生變化；公司將按預期開發其產品，並將達到預期的結果；未來對MINDCURE的產品會有需求；不會產生意想不到的費用或成本；MINDCURE將公司達成的戰略夥伴關係將創造預期的機會和結果；MINDCURE將促進全球的健康；在場外交易市場(OTCQX)的交易將吸引額外的投資，併為股東提供額外的流動性。
Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: successful clinical studies relating to ibogaine and the Desire Project, successfully synthesizing and manufacturing of ibogaine, the successful development, integration and deployment of iSTRYM, the successful development of appropriate Ketamine protocols, and acquiring adequate protection of any IP developed. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.
提供前瞻性信息的目的是提供有關管理層目前對未來的期望和計劃的信息，請讀者注意，此類陳述可能不適用於其他目的。前瞻性信息本身就包含有關未來和實際結果的已知和未知的風險和不確定性，涉及重大風險和不確定性，不應被解讀為對未來業績或結果的保證，因為實際結果可能與此類前瞻性信息中明示或暗示的結果大不相同。這些風險和不確定性包括但不限於與ibogaine和Desire Project有關的成功臨牀研究、ibogaine的成功合成和製造、iSTRYM的成功開發、整合和部署、適當的氯胺酮協議的成功開發以及對所開發的任何知識產權獲得足夠的保護等風險。儘管MINDCURE試圖確定可能導致實際結果、業績或成就與前瞻性信息中描述的結果、業績或成就大不相同的重要因素，但可能還有其他因素導致結果、業績或成就與預期、估計或預期的結果、業績或成就大不相同。因此，讀者不應過分依賴任何前瞻性陳述，因為不能保證前瞻性信息。
Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
除非適用的證券法另有要求，否則前瞻性陳述只在作出之日發表，MINDCURE不承擔公開更新或修改任何前瞻性信息的義務，無論是由於新信息、未來事件或其他原因。
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
CSE既不批准也不反對本新聞稿的內容，CSE不對本新聞稿的充分性或準確性承擔責任。
SOURCE Mind Cure Health Inc.
來源：Mind Cure Health Inc.
